- Home
- EIM vs DNTH Comparison
EIM vs DNTH Comparison
Compare EIM & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIM
- DNTH
- Stock Information
- Founded
- EIM 2002
- DNTH 2015
- Country
- EIM United States
- DNTH United States
- Employees
- EIM N/A
- DNTH N/A
- Industry
- EIM Finance/Investors Services
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- EIM Finance
- DNTH Health Care
- Exchange
- EIM Nasdaq
- DNTH Nasdaq
- Market Cap
- EIM 749.2M
- DNTH 823.1M
- IPO Year
- EIM N/A
- DNTH N/A
- Fundamental
- Price
- EIM $10.45
- DNTH $23.36
- Analyst Decision
- EIM
- DNTH Strong Buy
- Analyst Count
- EIM 0
- DNTH 8
- Target Price
- EIM N/A
- DNTH $46.43
- AVG Volume (30 Days)
- EIM 215.2K
- DNTH 292.8K
- Earning Date
- EIM 01-01-0001
- DNTH 11-07-2024
- Dividend Yield
- EIM 4.32%
- DNTH N/A
- EPS Growth
- EIM N/A
- DNTH N/A
- EPS
- EIM N/A
- DNTH N/A
- Revenue
- EIM N/A
- DNTH $5,366,000.00
- Revenue This Year
- EIM N/A
- DNTH $44.94
- Revenue Next Year
- EIM N/A
- DNTH N/A
- P/E Ratio
- EIM N/A
- DNTH N/A
- Revenue Growth
- EIM N/A
- DNTH 51.41
- 52 Week Low
- EIM $8.61
- DNTH $6.58
- 52 Week High
- EIM $10.51
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- EIM 45.61
- DNTH 29.54
- Support Level
- EIM $10.44
- DNTH $27.41
- Resistance Level
- EIM $10.56
- DNTH $28.56
- Average True Range (ATR)
- EIM 0.10
- DNTH 1.86
- MACD
- EIM 0.01
- DNTH -0.50
- Stochastic Oscillator
- EIM 62.07
- DNTH 11.61
About EIM Eaton Vance Municipal Bond
Eaton Vance Municipal Bond Fund is a non-diversified closed-end management investment company. It consists of Municipal bond fund, California municipal bond fund, and New York municipal bond fund. The company's investment objective is to provide current income exempt from regular federal income tax, alternative minimum tax, and taxes in specified states. Its investment plan is to invest in higher quality bonds.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.